Tofacitinib is clinically used for Rheumatoid Arthritis (RA).
The trends of using Tofacitinib in the medical practice has been changing over the time.
In the year 2016, around 5% doctors used to prefer Tofacitinib
whenever indication for a Disease-modifying antirheumatic drugs (DMARDs)
came-across in clinical management. Presently, approx 17% doctors prefer
Tofacitinib for clinical indication;
is expected to increased 30% over the
forecast period of 2020 - 2022.
A simultaneous changes in the preference is expected for other Disease-modifying antirheumatic drugs (DMARDs).
In addition, an increased incidence of
related diseases are presumed to be the
key contributing factors providing a
fillip this generic vertical.
Increased awareness, availability of
drugs by the key companies, rising
demand for improved healthcare are some of the major factors.
Furthermore, the presence of high unmet
clinical needs with regard to treatment issue is the factor propelling
the expansion of this vertical.
This modality of treatment is expected
to gain popularity in the coming years as generic provides better
Request us for your brand report
Brand report includes -
- Present Market share of your brand
- Current & future performance of your brand
- Promotional status of your brand
- Strategic market management of your brand
- And many more